Objective: Learn about the status of laboratory testing relapse after neonatal jaundice phototherapy.Methods: Sample of phototherapy full-term neonatal children with high blood bilirubin 222 cases, divided into 2 groups, according to the treatment result Relapse Group After phototherapy (31 cases), and NO Relapse Group After phototherapy (191 cases).Observing key laboratory test index of two groups such as G6PD, blood, blood routine, liver meritorious service etc.Results: Before Phototherapy, the Hb of Relapse Group After Phototherapy (149.63±14.71)g/l is obviously lower than these (156.02±17.90) g/l of NO Relapse After Phototherapy Group, t=2.169, P=0.035.After Phototherapy, the incidence of ABO hemolytic disease of newborn of Relapse Group is (16.13%) significantly higher than those(4.71%) of NO Relapse Grou , t = 5.857, P = 0.016;And the difference between other indicators of the two groups of neonate has no statistical significance (P < 0.050).Those indicators are AFP, ALT, AST, TBIL, HCT, MCHC and G6PD. Conclusion:Relapse of full-term neonatal jaundice after phototherapy may be related to lower hemoglobin concentration and ABO hemolytic disease. In order to improve curative effect, these risk factors should be taken into consideration when making Follow-up plan after phototherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.